SARS-CoV-2

Low booster rates and immune-evading SARS-CoV-2 variants could spell bad news, experts say. 

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.  

See some of the coolest images recently featured by The Scientist

The results from two large clinical trials don't support the idea that supplements of the vitamin bolster immune defenses against SARS-CoV-2.

Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.

The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.

The Scientist spoke with Maximilien Chaumon about his database showing how COVID-19 related lockdowns warped more 2,800 people’s perception of time.

The 81-year-old director says that he will step back from his positions this December, but that he will continue working to advance science and public health.

Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.

BA.2.75 is spreading rampantly in India and has so far reached at least 20 other countries, but it doesn’t seem to be outcompeting other Omicron SARS-CoV-2 subvariants.

Ana Teresa Freitas discusses how individual variation in vitamin D synthesis and metabolism influences susceptibility to upper respiratory viruses.

Studies show that a fourth mRNA vaccine dose offers the elderly and other high-risk groups strong protection against hospitalization and death from COVID-19, but experts say benefits for other populations may be more limited.